Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
1577222-14-0
Molecular formula
C11H13NO6
Molecular weight
255.22 g/mol
Drug class
Fumarate prodrugdisease-modifying therapy for multiple sclerosis
Mechanism of action
Rapidly hydrolysed to monomethyl fumarate (MMF), the same active metabolite formed from dimethyl fumarate. The mechanism of MMF in multiple sclerosis is not fully understood; Nrf2 pathway activation and modulation of inflammatory and oxidative-stress responses are proposed.
Indications / reported uses
Treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease, under the applicable product label.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Diroximel PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Diroximel Permitted Daily Exposure (PDE) report (the Diroximel PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Diroximel Occupational Exposure Limit (OEL) report (the Diroximel OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.